The arsenal for the treatment of metastatic melanoma is limited. A new approach to therapy using checkpoint blockade has improved overall survival in this patient population. Ipilimumab a CTLA-4 monoclonal antibody is a first in class drug that has pioneered this revolution. In this review, the authors provide an account of the different stages that led to the development of ipilimumab, its approval in the clinical setting for the treatment of advanced melanoma and ongoing investigations of combinatorial immune therapy.
Pharmacology, Toxicology and Pharmaceutical Science
6
7%
Agricultural and Biological Sciences
5
6%
Immunology and Microbiology
3
4%
Other
3
4%
Unknown
41
51%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 November 2016.
All research outputs
#27,763,431
of 34,410,315 outputs
Outputs from Future Oncology
#1,983
of 2,762 outputs
Outputs of similar age
#342,956
of 451,775 outputs
Outputs of similar age from Future Oncology
#28
of 33 outputs
Altmetric has tracked 34,410,315 research outputs across all sources so far. This one is in the 16th percentile – i.e., 16% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,762 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,775 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
